Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis
Aethlon Medical has entered a definitive all-stock merger agreement with privately held North Immunology, and the combined company will operate as North Immunology, Inc., trading on Nasdaq under the new ticker NRTX. A concurrent oversubscribed $180 million private placement, backed by healthcare investors including Bain Capital Life Sciences, Janus Henderson and Farallon Capital, is expected to fund operations into the second half of 2028, with the combined company carrying a pro forma equity value of approximately $346.5 million.
Key figures
- Drug Name
- NOR-101
- Deal Value Usd
- 346500000
- Phase Of Trial
- Phase 1a (expected to begin Q1 2027)
- Cash runway
- into the second half of 2028
- Nhp half life
- approximately 42-day
- Phase 1a start
- Q1 2027
- Phase 1b 2b topline
- 2028
- Interim pk safety data
- mid-2027
- North holder ownership
- approximately 95.25%
- Pro forma equity value
- 346500000
- Aethlon holder ownership
- approximately 4.75%
- Note conversion included
- 34000000
- Private placement gross proceeds
- 180000000
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.